Nanobiotix S.A. (NANO.PA) surged 18.41% intraday to €31.20 on 05 Mar 2026 after fresh clinical updates and heavy volume. The jump makes NANO.PA stock one of today’s top gainers on EURONEXT in Europe with 255074.00 shares traded versus average volume 158667.00. We outline the news links, key financial ratios, technicals and a Meyka AI grade and forecast to frame the move for traders and longer-term investors.

Intraday move and immediate catalysts for NANO.PA stock

Nanobiotix S.A. (NANO.PA) rose from an open of €29.85 to a high of €31.65, closing intraday at €31.20, a €4.85 gain or 18.41%. Volume spiked to 255074.00, a relative volume of 2.53, suggesting strong buy-side interest. Market commentary links the rally to fresh Phase 1/expansion data and renewed attention to the Janssen collaboration, which traders say supports upside momentum.

Fundamentals and valuation snapshot for NANO.PA stock

Nanobiotix trades on EURONEXT in EUR with a market cap of €1,398,152,580.00 and shares outstanding 48,378,982.00. The company posts EPS -1.09 and a trailing PE of -26.51, reflecting ongoing losses. Price averages sit at 50-day €19.69 and 200-day €13.32, indicating a significant multi-month uptrend versus fundamentals. Current ratios and cash per share remain tight; cash per share is 0.61 and current ratio 0.63, underlining funding and execution risk.

Clinical updates, newsflow and links to sources

Recent data releases — including Phase 1 readouts for JNJ-1900 (NBTXR3) in multiple indications — have driven positive sentiment. Nanobiotix published study updates and voting-rights notices in recent weeks. Read company materials and aggregated coverage via the corporate site and market coverage for context: Nanobiotix press releases and investor updates and broader coverage on StockAnalysis summary of NBTX data.

Technical picture and trading stats for NANO.PA stock

Technically, NANO.PA shows strong momentum: RSI 79.90 (overbought), MACD histogram 0.67 and ADX 38.56 indicating a strong trend. Bollinger mid is €22.21 while the upper band is €27.80, so today’s price sits above the upper band. Short-term traders should note ATR 1.61 and MFI 79.64, both signalling elevated volatility and potential for pullbacks after large intraday gains.

Meyka AI rates NANO.PA with a score out of 100 and valuation context

Meyka AI rates NANO.PA with a score of 73.82 out of 100 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Despite the positive score, valuation multiples such as price-to-sales 243.58 and negative PE show investor expectations are priced for clinical success, increasing binary risk.

Meyka AI’s forecast model projects and price scenarios

Meyka AI’s forecast model projects monthly €21.03, quarterly €27.44, yearly €25.46, and three-year €46.20. Compared with the current price €31.20, the one-year projection implies a downside of -18.40%, while the three-year view implies an upside of +48.08%. Forecasts are model-based projections and not guarantees; outcome depends on trial outcomes, partner decisions, and funding.

Final Thoughts

NANO.PA stock led EURONEXT gainers on 05 Mar 2026 after clinical updates and heavy volume pushed the price to €31.20, up 18.41% intraday. Fundamentals remain mixed: EPS -1.09, trailing PE -26.51, and tight liquidity metrics underline execution risk. Technically, momentum is strong but overbought indicators warn of short-term retracements. Meyka AI rates NANO.PA 73.82/100 (B+, BUY) and projects a one-year level of €25.46 (implied -18.40%) and a three-year target €46.20 (implied +48.08%). Traders may favour short-term setups on momentum while longer-term investors should weigh clinical milestones, partner commitments, and cash runway. For live coverage and data-driven alerts use our AI-powered market analysis platform at Meyka AI and monitor company releases for catalyst timing. Remember, forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.